Completed PHASE2 INTERVENTIONAL 1-arm NCT01965613

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Sponsor: Janssen Research & Development, LLC

Interventions Xilonix

Updated 12 times since 2017 Last updated: Jul 6, 2025 Started: Jan 31, 2014 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Pyoderma Gangrenosum, this trial is completed. The trial is conducted by Janssen Research & Development, LLC and has accumulated 12 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Aug 2025 — Present [monthly]

Completed PHASE2
Apr 2025 — Aug 2025 [monthly]

Completed PHASE2
Feb 2025 — Apr 2025 [monthly]

Completed PHASE2
Jan 2025 — Feb 2025 [monthly]

Completed PHASE2
Sep 2024 — Jan 2025 [monthly]

Completed PHASE2

▶ Show 7 earlier versions

Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Feb 2021 — Apr 2022 [monthly]

Completed PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tallahassee, United States